1
EXHIBIT 10.10
[SMITHKLINE XXXXXXX PHARMACEUTICALS LETTERHEAD]
CORIXA CORPORATION
0000 Xxxxxxxx Xxxxxx, Xxxxx 000
Xxxxxxx, Xxxxxxxxxx, 00000
XXX
VIA FAX
CONFIRMATION SENT BY MAIL
Rixensart, February 1, 1997
Dear Sirs:
RE: TUBERCULOSIS COLLABORATION AND LICENSE AGREEMENT - RESEARCH PROGRAM
We refer to the Tuberculosis Collaboration and License Agreement between Corixa
Corporation ("Corixa") and SmithKline Xxxxxxx Biologicals S.A. ("SB") dated
October 6, 1995 ("Agreement").
We are pleased to notify you hereby, in accordance with Section 5(c) of the
above referred Agreement, of our intention to renew the Research Program for a
further period of one year from June 1, 1997 to May 31, 1998. A technology
access fee of US $[***] will be paid by SB to Corixa in quarterly
installments of $[***] each, to be reinvested in full in accordance with
Section 10(b) of the Agreement. The Option granted by Xxxxxx to SB pursuant to
Section 4(a) of the Agreement will accordingly be extended for a further one
year period starting on September 1, 1997 and ending on August 30, 1998.
For the sake of good order, would you please sign and return to us the copy of
this letter which is being sent to you in duplicate.
Sincerely yours,
/s/ XXXX XXXXXXXXX
----------------------
Xxxx Xxxxxxxxx
Xxxxxx Vice-President,
General Manager
AGREED AND ACCEPTED FOR AND ON BEHALF OF
CORIXA CORPORATION
/s/ XXXX XXXXXX
------------------------------
Name: Xxxx XxXxxx
Title: Chief Operating Officer
Date: 25 February, 1997
